Protein Kinase Inhibitors: all 15,278 studies that test it

Page 123 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market ProductCompletedNCT01906125Phase 1
• Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesCompletedNCT01905813Phase 1
• A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic CancerCompletedNCT01905111Phase 1
• Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular CarcinomaCompletedNCT01903694Phase 3
• A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00CompletedNCT01903018Phase 2
• Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
• Phase II Study of Regorafenib in Metastatic Soft Tissue SarcomaCompletedNCT01900743Phase 2
• A Phase I Study of LEE011 in Asian PatientsCompletedNCT01898845Phase 1
• An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaCompletedNCT01898585Phase 4
• Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in ChildrenTerminatedNCT01898377Phase 2
• A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT01897116Phase 1
• A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular CarcinomaCompletedNCT01897038Phase 1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
• CC-223 and Ketoconazole Drug-Drug Interaction StudyCompletedNCT01896323Phase 1
• Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01895842Phase 1
• Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male SubjectsCompletedNCT01894399Phase 1
• Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular MelanomaCompletedNCT01893099Phase 1
• Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High SubjectsCompletedNCT01892527Phase 2
• Cardiac Allograft Remodeling and Effects of SirolimusTerminatedNCT01889992Phase 1
• Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial CarcinomaWithdrawnNCT01888562Not applicable
• Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or SurgeryCompletedNCT01888302Phase 1
• Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney CancerTerminatedNCT01888042Phase 2
• Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised StudyCompletedNCT01887795Phase 3
• Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young AdultsTerminatedNCT01887522Phase 2
• Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01886859Phase 1
• Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male SubjectsCompletedNCT01886209Phase 1
• Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young AdultsCompletedNCT01884922Phase 1
• Exploring the Activity of RAD001 in Vestibular Schwannomas and MeningiomasCompletedNCT01880749Early Phase 1
• Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT01880567Phase 2
• A Phase II Study of Anlotinib in STS PatientsCompletedNCT01878448Phase 2
• Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid TumorsCompletedNCT01877811Phase 1
• A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT01877005Phase 2
• Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus CobimetinibTerminatedNCT01876641Phase 1
• A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT01875705Phase 1
• Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + LapatinibCompletedNCT01875666Early Phase 1
• Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal CancerCompletedNCT01875380Phase 2
• A Phase II Study of Anlotinib in MTC PatientsCompletedNCT01874873Phase 2
• Masitinib in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT01872598Phase 3
• Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT01872442Phase 2
• Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast CancerActive, not recruitingNCT01872260Phase 1/2
• Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified ChemotherapyActive, not recruitingNCT01871766Phase 2
• Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
• CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung CancerTerminatedNCT01871480Phase 2
• A Phase I Study of Nilontinib and Cetuximab in Patients With Solid TumorsTerminatedNCT01871311Phase 1
• Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural MesotheliomaTerminatedNCT01870609Phase 2
• Nilotinib Plus Pegylated Interferon-α2b in CMLTerminatedNCT01866553Phase 2
• A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy ParticipantsCompletedNCT01866033Phase 1
• Combination of Metformin With Gefitinib to Treat NSCLCCompletedNCT01864681Phase 2
• Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's DiseaseCompletedNCT01864655Phase 1
• Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant DiseaseWithdrawnNCT01864070Phase 1
• Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in ChinaCompletedNCT01863485Phase 1
• A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung CancerCompletedNCT01862081Phase 1
• Phase I/II Trial of Antagonism of HER in GI CancerCompletedNCT01862003Phase 2
• A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue SarcomaCompletedNCT01861951Phase 2
• Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
• Afatinib Plus Nimotuzumb for NSCLCStatus unknownNCT01861223Phase 1/2
• Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung CancerStatus unknownNCT01861197Phase 2
• Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid TumoursTerminatedNCT01859351Phase 1
• Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
• A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationCompletedNCT01859026Phase 1
• Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01858883Phase 1/2
• Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCompletedNCT01857193Phase 1
• Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ CellsCompletedNCT01856283Phase 2
• Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based ChemotherapyTerminatedNCT01856101Phase 2
• Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISHCompletedNCT01855854Phase 2
• Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedNCT01854606Phase 1
• Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamCompletedNCT01853423Phase 1
• Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard TherapyCompletedNCT01853319Phase 3
• A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01851824Phase 1
• A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AloneCompletedNCT01851707Phase 2
• Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaWithdrawnNCT01851408Phase 2
• Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional RegimenStatus unknownNCT01850147Phase 2
• Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic MalignanciesTerminatedNCT01849744Phase 1
• A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic MalignancyCompletedNCT01849666Phase 1
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent GlioblastomaCompletedNCT01849146Phase 1
• Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial TractCompletedNCT01844947Phase 1
• A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic MalignanciesCompletedNCT01844674Phase 1
• Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)WithdrawnNCT01843998Phase 2
• Radiation Use During Vemurafenib TreatmentWithdrawnNCT01843738Phase 1
• Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC PatientsStatus unknownNCT01843647Phase 2
• Ibrutinib in Treating Patients With Relapsed Hairy Cell LeukemiaActive, not recruitingNCT01841723Phase 2
• Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF MutationSuspendedNCT01841463Phase 1
• Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on SorafenibActive, not recruitingNCT01840592Phase 2
• Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT01838434Phase 1
• IPI-145 ADME and Absolute Bioavailability StudyCompletedNCT01836861Phase 1
• Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedNCT01836705Phase 1
• Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive ChemoradiationWithdrawnNCT01836341Phase 1
• First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese SubjectsCompletedNCT01835197Phase 1
• Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryTerminatedNCT01835184Phase 1
• Tivozanib + Gemcitabine in Metastatic RCCWithdrawnNCT01834183Phase 2
• A Phase I Study of Anlotinib on Tolerance and PharmacokineticsCompletedNCT01833923Phase 1
• Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)CompletedNCT01833572Phase 2
• A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid ArthritisCompletedNCT01830985Phase 2/3
• A Multicenter Phase II Pilot Open LabelStatus unknownNCT01830504Phase 2
• Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AMLCompletedNCT01830361Phase 2
• RAD001 in Advanced SarcomaCompletedNCT01830153Phase 2
• A Study of Famitinib in Patients With Advanced Metastatic Renal Cell CancerCompletedNCT01829841Phase 2
• Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT01829568Phase 1
• Neoadjuvant Rapamycin in Patients Undergoing Radical CystectomyCompletedNCT01827618Early Phase 1
• Study of Dasatinib, Androgen Deprivation Therapy and RadiationWithdrawnNCT01826838Phase 1

← Protein Kinase Inhibitors overview